Immix Biopharma, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
| Przychód (średnia) |
1.00 |
7.00 |
12.14 |
85.00 |
198.00 |
| Przychód Δ r/r |
0.00% |
600.00% |
73.44% |
600.11% |
132.94% |
| Przychód (min) |
1.00 |
7.00 |
12.14 |
85.00 |
198.00 |
| Przychód (max) |
1.00 |
7.00 |
12.14 |
85.00 |
198.00 |
| EBITDA (średnia) |
0.82 |
5.73 |
9.94 |
69.56 |
162.03 |
| EBIT (średnia) |
0.82 |
5.73 |
9.94 |
69.56 |
162.04 |
| EBIT % |
81.84% |
81.84% |
81.84% |
81.84% |
81.84% |
| Zysk netto (średni) |
-22.49 |
-16.83 |
-21.50 |
23.48 |
77.22 |
| Zysk netto % |
-2248.71% |
-240.43% |
-177.06% |
27.62% |
39.00% |
| EPS (średnia) |
-0.80 |
-0.59 |
-0.76 |
0.83 |
2.73 |
| Liczba analityków (Przychody) |
1 |
1 |
2 |
1 |
1 |
| Liczba analityków (EPS) |
1 |
1 |
2 |
1 |
1 |
| symbol |
IMMX |
IMMX |
IMMX |
IMMX |
IMMX |